UCB (UCBJY) Upgraded to Strong Buy: What Does It Mean for the Stock?
Werte in diesem Artikel
UCB SA (UCBJY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.As such, the Zacks rating upgrade for UCB is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.For UCB, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.Harnessing the Power of Earnings Estimate RevisionsAs empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .Earnings Estimate Revisions for UCBFor the fiscal year ending December 2025, this company is expected to earn $4.23 per share, which is unchanged compared with the year-ago reported number.Analysts have been steadily raising their estimates for UCB. Over the past three months, the Zacks Consensus Estimate for the company has increased 0.6%.Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.You can learn more about the Zacks Rank here >>> The upgrade of UCB to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They includeStock #1: A Disruptive Force with Notable Growth and ResilienceStock #2: Bullish Signs Signaling to Buy the DipStock #3: One of the Most Compelling Investments in the MarketStock #4: Leader In a Red-Hot Industry Poised for GrowthStock #5: Modern Omni-Channel Platform Coiled to SpringMost of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.Download Atomic Opportunity: Nuclear Energy's Comeback free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UCB SA (UCBJY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Ausgewählte Hebelprodukte auf UCB
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf UCB
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu UCB S.A.
Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv
Analysen zu UCB S.A.
Datum | Rating | Analyst | |
---|---|---|---|
14.12.2012 | UCB hold | Deutsche Bank AG | |
07.11.2012 | UCB hold | ING | |
30.10.2012 | UCB outperform | Exane-BNP Paribas SA | |
27.09.2012 | UCB overweight | Morgan Stanley | |
27.09.2012 | UCB hold | ING |
Datum | Rating | Analyst | |
---|---|---|---|
30.10.2012 | UCB outperform | Exane-BNP Paribas SA | |
27.09.2012 | UCB overweight | Morgan Stanley | |
17.09.2012 | UCB overweight | Morgan Stanley | |
02.08.2012 | UCB buy | Société Générale Group S.A. (SG) | |
23.07.2012 | UCB overweight | Morgan Stanley |
Datum | Rating | Analyst | |
---|---|---|---|
10.09.2012 | UCB underperform | Cheuvreux SA | |
03.09.2007 | SCHWARZ PHARMA reduzieren | AC Research | |
07.03.2007 | SCHWARZ PHARMA Einstellung der Coverage | Nord LB | |
27.02.2007 | SCHWARZ PHARMA verkaufen | M.M. Warburg | |
26.02.2007 | SCHWARZ PHARMA reduzieren | AC Research |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für UCB S.A. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen